All finerenone dose groups exhibited a similar proportion of patients with > 30% decline in NT-proBNP compared to the eplerenone group and the pre-specified exploratory composite CV clinical endpoint including all-cause death, CV-hospitalizations, or emergency presentation for worsening heart failure occurred numerically less frequently with finerenone compared to eplerenone [5, 84]. This evidence concerns the gene NPPB and heart failure.